Study of IBI362 for liver scarring from MASH
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your body mass index (BMI) must be 25 or higher.
- You must have a confirmed diagnosis of MASH with moderate to advanced liver scarring (stage F2 or F3) based on a recent liver biopsy.
- Your liver disease should not be caused by other conditions like hepatitis B or C, HIV, or certain other liver diseases.
- Your liver and overall health must meet specific safety criteria (such as not having severe liver failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This study tests an investigational drug called ALN-CIDEB for people with MASH, a liver condition linked to metabolic issues, that has caused moderate liver scarring. The goal is to see if the drug can reduce liver damage and improve liver health.
This study tests an investigational medicine called pemvidutide to see if it can reduce liver scarring in people with MASH (a liver condition linked to excess weight and metabolic issues). It may help improve liver health and potentially slow or reverse the condition.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This trial tests an experimental drug for people with a type of fatty liver disease called MASH that has led to liver scarring. The goal is to see if the drug can help reduce liver damage and improve liver health.
Hear when a new Metabolic Dysfunction-associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.